TABLE 2

Adverse events

	Placebo	PRM-151				All
	Placebo	1 mg·kg⁻¹	5 mg·kg⁻¹	10 mg·kg⁻¹	All doses	All
Subjects	6	6	5	4	15	21
Cough	2 (33)	4 (67)	3 (60)	0 (0)	7 (47)	9 (43)
Productive cough	2 (33)	1 (17)	2 (40)	1 (25)	4 (27)	6 (29)
Fatigue	1 (17)	0 (0)	2 (40)	1 (25)	3 (20)	4 (19)
Headache	1 (17)	2 (33)	0 (0)	1 (25)	3 (20)	4 (19)
Dyspnoea	2 (33)	2 (33)	0 (0)	0 (0)	2 (13)	4 (19)
Dizziness	1 (17)	1 (17)	1 (20)	0 (0)	2 (13)	3 (14)
Pruritus	1 (17)	1 (17)	1 (20)	0 (0)	2 (13)	3 (14)
Haematoma	1 (17)	2 (33)	0 (0)	0 (0)	2 (13)	3 (14)
Dyspnoea upon exertion	2 (33)	1 (17)	0 (0)	0 (0)	1 (7)	3 (14)
Nasopharyngitis	2 (33)	1 (17)	0 (0)	0 (0)	1 (7)	3 (14)
Back pain	2 (33)	0 (0)	1 (20)	0 (0)	1 (7)	3 (14)
Dysphonia	0 (0)	2 (33)	0 (0)	0 (0)	2 (13)	2 (10)
Hypotension	0 (0)	1 (17)	0 (0)	1 (25)	2 (13)	2 (10)
Lymphadenopathy	1 (17)	1 (17)	0 (0)	0 (0)	1 (7)	2 (10)
Catheter site haematoma	1 (17)	1 (17)	0 (0)	0 (0)	1 (7)	2 (10)
Malaise	1 (17)	1 (17)	0 (0)	0 (0)	1 (7)	2 (10)
Hypertension	1 (17)	1 (17)	0 (0)	0 (0)	1 (7)	2 (10)
Noncardiac chest pain	2 (33)	0 (0)	0 (0)	0 (0)	0 (0)	2 (10)
Vomiting	2 (33)	0 (0)	0 (0)	0 (0)	0 (0)	2 (10)

Data are presented as n or n (%). Events reported by at least two (10%) out of the 21 subjects are listed. Treatment-emergent adverse events were defined as events occurring from the first day of dosing to the end of the study (day 57 or early termination day).